PDJ: Hemoglobin A1c Test System
What it covers
Quantitative determination of Hemoglobin A1c to aid in the diagnosis of diabetes.
FDA’s definition of product code PDJ, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K260468 | H100Plus Hemoglobin Testing System | Shenzhen Lifotronic Technology Co., Ltd. | Oct 2, 2026 | Traditional |
| K252749 | Medconn 8K Glycated Hemoglobin Test System | Shanghai Medconn Medical Technology Co., Ltd. | Jan 6, 2026 | Traditional |
| K250073 | Tosoh Automated Glycohemoglobin Analyzer HLC-723GR01 | Tosoh Bioscience, Inc. | Oct 3, 2025 | Traditional |
| K242911 | Medconn Glycated Hemoglobin Test system | Shanghai Medconn Medical Technology Co., Ltd. | Jun 20, 2025 | Traditional |
| K220999 | Hipro Glycosylated Hemoglobin (HbA1c) Test System | Shijiazhuang Hipro Biotechnology Co., Ltd. | Sep 12, 2024 | Traditional |
| K200904 | Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 | Tosoh Bioscience, Inc. | Aug 5, 2021 | Traditional |
| K200256 | ADVIA Chemistry Enzymatic Hemoglobin Ale (Alc_E) Assay | Siemens Healthcare Diagnostics, Inc. | Jul 2, 2021 | Special |
| K193053 | Tina-quant Hemoglobin A1cDx Gen.3 | Roche Diagnostics Operations (Rdo) | Mar 26, 2020 | Traditional |
| K182651 | HbA1c Advanced | Beckman Coulter Ireland, Inc. | Jan 16, 2019 | Traditional |
| K182988 | Afinion HbA1c Dx on Afinion 2 | Alere Technologies AS | Nov 29, 2018 | Special |
Clearances by year
27 PDJ 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 2 | 181 |
| 2025 | 2 | 268 |
| 2024 | 1 | 892 |
| 2021 | 2 | 501 |
| 2020 | 1 | 146 |
| 2019 | 1 | 114 |
| 2018 | 5 | 203 |
| 2017 | 3 | 173 |
| 2016 | 2 | 207 |
| 2015 | 4 | 234 |
| 2014 | 2 | 315 |
| 2013 | 2 | 246 |
Who submits
16 applicants cleared a PDJ device since 2011. 67% of the clearances went to applicants in United States, then China (15%), Norway (7%) and Canada (4%). By type: Traditional 89%, Special 7% and Post-NSE 4%.
| Applicant | Clearances since 2011 |
|---|---|
| Bio-Rad Laboratories, Inc. | 3 |
| Siemens Healthcare Diagnostics, Inc. | 3 |
| Tosoh Bioscience, Inc. | 3 |
| Abbott Laboratories | 2 |
| Alere Technologies AS | 2 |
| Roche Diagnostics Operations (Rdo) | 2 |
| Sebia | 2 |
| Shanghai Medconn Medical Technology Co., Ltd. | 2 |
How FDA classifies it
Class II (special controls). The special controls for this device are:
(1) The device must have initial and annual standardization verification by a certifying glycohemoglobin standardization organization deemed acceptable by FDA.
(2) The premarket notification submission must include performance testing to evaluate precision, accuracy, linearity, and interference, including the following:
(i) Performance testing of device precision must, at a minimum, use blood samples with concentrations near 5.0 percent, 6.5 percent, 8.0 percent, and 12 percent hemoglobin A1c. This testing must evaluate precision over a minimum of 20 days using at least three lots of the device and three instruments, as applicable.
(ii) Performance testing of device accuracy must include a minimum of 120 blood samples that span the measuring interval of the device and compare results of the new device to results of a standardized test method. Results must demonstrate little or no bias versus the standardized method.
(iii) Total error of the new device must be evaluated using single measurements by the new device compared to results of the standardized test method, and this evaluation must demonstrate a total error less than or equal to 6 percent.
(iv) Performance testing must demonstrate that there is little to no interference from common hemoglobin variants, including Hemoglobin C, Hemoglobin D, Hemoglobin E, Hemoglobin A2, and Hemoglobin S.
(3) When assay interference from Hemoglobin F or interference with other hemoglobin variants with low frequency in the population is observed, a warning statement must be placed in a black box and must appear in all labeling material for these devices describing the interference and any affected populations.
From 21 CFR 862.1373. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 862.1373 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent PDJ clearances declared.
Ask about PDJ
Questions about PDJ
What is FDA product code PDJ?
Product code PDJ, “Hemoglobin A1c Test System” in FDA's classification database, is a Class II device type under 21 CFR 862.1373 (hemoglobin A1c test system), reviewed by FDA's Clinical Chemistry panel. FDA's 510(k) database lists 27 clearances under PDJ, 27 of them since 2011.
How many 510(k) clearances are there under PDJ?
FDA’s 510(k) database listed 27 clearances under PDJ as of Oct 29, 2026, 27 of them decided since 2011; the most recent decision was Oct 2, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a PDJ 510(k)?
For the 4 PDJ clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 249 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most PDJ clearances?
Since 2011: Bio-Rad Laboratories, Inc. (3), Siemens Healthcare Diagnostics, Inc. (3), Tosoh Bioscience, Inc. (3), Abbott Laboratories (2) and Alere Technologies AS (2). 16 applicants have cleared a PDJ device in that time.